2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one

217.31 g/mol

217.146664230 g/mol

DTXSID80331167

L01XX24|L - Antineoplastic and immunomodulating agents

20.3 Ų

Some abnormalities of liver test results occur in almost all patients treated with either asparaginase or pegaspargase. Most typical is a decrease in serum albumin and clotting factors (including II, V, VII, VIII, IX, prothrombin and fibrinogen) due to inhibition of hepatic protein synthesis. Most patients also have a rise in alkaline phosphatase levels and a lower proportion have increases in serum aminotransferase levels and bilirubin. Symptoms of fatigue and anorexia may be present. The inhibition of clotting factor and thrombolytic activity rarely results in excess bleeding, but paradoxically can also cause excessive clotting and a hypercoagulable state. Serum aminotransferase elevations during asparaginase therapy are mild-to-moderate in severity (2 to 10 times the upper limit of normal) and self-limiting. The abnormalities typically arise after 2 to 3 weeks of therapy and resolve within 2 to 4 weeks of stopping.

Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.|Drug: Pegaspargase

Asparaginase is a bacterial enzyme that is used as an antineoplastic agent, largely in the therapy of acute lymphocytic leukemia. L-asparaginase has many side effects, one of which is hepatic injury that is characterized by inhibition of hepatic protein synthesis and steatosis, which can be severe and lead to death from hepatic failure.

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Oncaspar

Human drugs -> Oncaspar -> EMA Drug Category|Antineoplastic agents -> Human pharmacotherapeutic group